Search

The article discusses a study on Ankylosing Spondylitis (AS), an autoimmune disease that affects spinal joints and causes chronic pain. The research analyzed single-cell RNA sequencing data from AS patients and healthy controls to identify metabolic pathways and protein-protein interaction networks in specific immune cell types. The findings suggest increased purine metabolism flux, fatty acid degradation, and glycolysis in certain immune cells of AS patients compared to healthy individuals, with RPS11 identified as a significant hub that could potentially serve as a biomarker or therapeutic target for more precise treatments. [Extracted from the article]

Researchers at the University of Shanghai for Science and Technology have published a case report on using a halo-vest for one-stage surgery to treat simultaneous double spine fractures-dislocation in a patient with ankylosing spondylitis (AS). The study involved a 57-year-old male patient who showed significant improvement in pain and daily activities after the surgery. The researchers concluded that one-stage surgery with a halo-vest is an effective treatment option for such cases, based on their experience and a review of existing literature. [Extracted from the article]

A recent study from "Victor Babes" University of Medicine and Pharmacy in Timisoara, Romania, explores a rare overlap syndrome between ankylosing spondylitis (AS) and amyotrophic lateral sclerosis (ALS). The research details a case where a patient initially diagnosed with AS later developed ALS after treatment with TNF-a inhibitors. The study aims to shed light on the connection between AS and ALS, as well as the potential impact of TNF-a inhibitors on ALS development. For more information, the full article can be accessed for free at https://doi.org/10.3390/medicina60101703. [Extracted from the article]

A patent has been issued for anti-TNF antibodies, compositions, and methods for treating active ankylosing spondylitis by Janssen Biotech Inc. The patent discusses the role of TNF alpha in inflammatory diseases, autoimmune diseases, infections, and malignancies, and the development of antibodies to target TNF alpha for therapeutic purposes. The patent outlines specific sequences and methods for administering anti-TNF antibodies to treat active Psoriatic Arthritis, emphasizing safety and effectiveness in achieving positive outcomes for patients. [Extracted from the article]

A recent study conducted at Henan Provincial People's Hospital focused on the effects of pedicle subtraction osteotomy on aortic morphology and hemodynamics in patients with ankylosing spondylitis and kyphosis. The research utilized finite element analysis to simulate hemodynamic changes during osteotomy and found that blood flow velocity, blood pressure, and wall shear stress decreased postoperatively. The study suggests potential cardiovascular benefits of osteotomy in patients with ankylosing spondylitis. For more information, the full article can be accessed for free at the provided link. [Extracted from the article]

Research from Qingdao University explores the causal relationship between ankylosing spondylitis (AS) and ocular inflammatory diseases using Mendelian randomization analysis. The study found a significantly increased risk of uveitis, iridocyclitis, scleritis, and episcleritis associated with AS, but no correlation with keratitis and optic neuritis. These findings may offer insights for preventing AS complications. The study was published in Frontiers in Genetics and can be accessed for free online. [Extracted from the article]

Research from the V.A. Nasonova Research Institute of Rheumatology explores the development of syndesmophytes in ankylosing spondylitis (AS) patients through MRI and CT data comparison. The study suggests that syndesmophytes may not always coincide with areas of inflammation detected by MRI, indicating a complex relationship between bone formation and inflammation in AS. This research provides valuable insights into the pathogenesis of AS and highlights the importance of multidirectional imaging techniques in studying spinal injuries in AS patients. [Extracted from the article]

Recent studies from the V.A. Nasonova Research Institute of Rheumatology focus on ankylosing spondylitis, a condition that often leads to hip joint inflammation and early disability. The research highlights the effectiveness of tumor necrosis factor-a inhibitors in treating hip joint inflammation in patients with ankylosing spondylitis, potentially inhibiting the progression of coxitis over a two-year period. This study provides valuable insights into the use of biologic therapy for patients with ankylosing spondylitis and coxitis, offering hope for improved treatment outcomes. [Extracted from the article]

Researchers at the Federal University Minas Gerais in Belo Horizonte, Brazil, conducted a study on the impact of spinal damage on the functional capacity of patients with axial spondyloarthritis (axSpA). They compared two radiographic scores and found that spinal damage was associated with physical function in axSpA, but to a lesser extent than disease activity and mobility. The study concluded that incorporating cervical facet joint assessment did not improve the ability to predict function. This research has been peer-reviewed and published in The Journal of Rheumatology. [Extracted from the article]

A recent study conducted at Ruhr-University Bochum in Germany focused on immune checkpoint signals in Ankylosing Spondylitis, a type of inflammatory disease affecting musculoskeletal and extra-musculoskeletal sites. The research highlighted the role of immune responses in chronic pain and immobility associated with the condition, emphasizing markers like PD-1 and CTLA-4 as potential targets for new treatment strategies. The study concluded that further investigation into immune checkpoint signaling could lead to a better understanding of the disease's pathogenesis and the development of innovative therapies. [Extracted from the article]

A recent study conducted at Ain Shams University in Cairo, Egypt, focused on the role of pulmonary rehabilitation in improving lung functions in patients with ankylosing spondylitis (AS). The study involved 30 participants diagnosed with radiographic axial spondyloarthropathy who underwent a pulmonary rehabilitation program. Results showed significant improvements in disease activity, functional parameters, and pulmonary function tests after completing the rehabilitation program. The researchers concluded that pulmonary rehabilitation, when combined with other interventions, can lead to improved respiratory function, disease activity, and overall functional activity in individuals with ankylosing spondylitis. [Extracted from the article]

A recent study from McGill University examined the obstetric and neonatal outcomes in women with Ankylosing Spondylitis (AS). The research, which analyzed data from the Healthcare Cost and Utilization Project, found that women with AS had a higher risk of cesarean delivery, gestational diabetes, placenta previa, small-for-gestational-age neonates, and intrauterine fetal death compared to those without AS. The study concluded that women diagnosed with AS face increased obstetric complications during pregnancy. [Extracted from the article]

Researchers from "Victor Babes" University of Medicine and Pharmacy in Timisoara, Romania, conducted a study on ankylosing spondylitis (AS) patients to analyze the relationship between myotonometry parameters and spinal mobility. The study found that AS patients who participated in an 8-week physical exercise program showed improvements in muscle properties and spinal motions. Significant correlations were noted between stiffness and spinal movements, indicating the potential benefits of physical exercise for AS patients. This research provides valuable insights into the management of AS through exercise interventions. [Extracted from the article]

Researchers at Air Force Medical University in Shaanxi, China, conducted a study on Ankylosing Spondylitis (AS), a chronic inflammatory joint disease. The study focused on the knockdown of SIGLEC1 to inhibit osteogenic differentiation and alleviate AS progression by suppressing the TGF-beta 1/SMAD signaling pathway. The research found that knockdown of SIGLEC1 promoted cell proliferation, inhibited osteogenic differentiation and inflammation, and suppressed the development of AS. This study was supported by the Xi'an Science and Technology Program and has been peer-reviewed. [Extracted from the article]

A systematic review and meta-analysis conducted by researchers at Henan University of Chinese Medicine evaluated the efficacy and safety of mind-body exercise interventions for patients with axial spondyloarthritis (axSpA). The study included Tai Chi, Yoga, Pilates, and Qigong as interventions. The analysis of 15 studies showed that mind-body exercise significantly improved physical function, disease activity, pain intensity, spinal mobility, and quality of life in patients with axSpA. The researchers concluded that mind-body exercise may be a promising non-pharmacological treatment for axSpA, but further rigorous studies are needed to confirm these findings. [Extracted from the article]

A recent study conducted in Odisha, India, evaluated the efficacy and safety of tofacitinib in patients with ankylosing spondylitis (AS). The study included patients aged 18 to 60 years who had active AS and had not responded well to non-steroidal anti-inflammatory drugs. The patients were randomly assigned to receive either tofacitinib or a placebo for 12 weeks. The results showed that tofacitinib was effective in reducing disease activity measures compared to the placebo. The study provides valuable insights into the potential benefits of tofacitinib for patients with AS. [Extracted from the article]

Researchers from the UKM Medical Center in Malaysia have conducted a study on ankylosing spondylitis (AS), an autoimmune and inflammatory arthritis. The study aimed to establish the association between AS and its comorbidities, such as axial spondyloarthritis, cardiovascular disease, Guillain-Barre syndrome, rheumatic fever, and vasculitis. Using network biology and computational methods, the researchers identified twelve shared pathways between AS and its comorbidities, which are involved in immune responses, inflammatory responses, and cellular signaling. These findings provide valuable insights into the pathobiological processes of AS and its comorbidities, aiding in accurate diagnosis and effective treatment. [Extracted from the article]

A study conducted at Kyung Hee University in Seoul, South Korea, aimed to determine the best method for selecting the vertebra for pedicle subtraction osteotomy (PSO) in corrective surgery for patients with ankylosing spondylitis (AS) and thoracolumbar kyphosis (TLK). The study analyzed the medical records of 235 AS patients with TLK who underwent PSO between May 2009 and August 2022. The researchers found that choosing the vertebra based on a specific method provided a greater degree of correction for sagittal imbalance. The proposed method is easily reproducible and can be used to determine the apex level in AS patients with TLK. [Extracted from the article]

A recent study conducted by researchers at Recep Tayyip Erdogan University in Turkey explored the relationship between ankylosing spondylitis (AS) and the presystolic wave (PW) detected on echocardiography. AS is a chronic inflammatory disease that affects the axial skeleton and can lead to cardiovascular complications. The study included 117 patients, with 64 diagnosed with AS and 53 without AS. The researchers found a significant correlation between PW and AS, suggesting that PW may be a useful marker for cardiovascular involvement in AS. Further research is needed to better understand this relationship. [Extracted from the article]

A recent study conducted at Harbin Medical University in China explored the use of positron emission tomography (PET) in the management of ankylosing spondylitis (AS), a condition characterized by inflammation and osteoblastic changes in the sacroiliac joint. The study found that PET imaging using an aluminum-[F-18]fuoride-labeled fibroblast activation protein inhibitor (FAPI) was highly sensitive to systemic arthritic changes in AS patients and correlated with clinical disease activity and laboratory tests. The researchers concluded that this imaging method shows promise for the early assessment of AS and monitoring disease progression. Further research is needed to validate these findings. [Extracted from the article]

Researchers from the University of Ulsan College of Medicine have conducted a pilot study to evaluate the diagnostic utility of anti-protein phosphatase magnesium-dependent 1A (PPM1A) IgM and IgG in patients with active ankylosing spondylitis (AS). The study found that anti-PPM1A-IgM levels were significantly lower in AS patients compared to healthy controls and patients with rheumatoid arthritis. The researchers concluded that decreased anti-PPM1A-IgM levels may have a potential role in the diagnosis of active AS. This research provides valuable insights into the development of biomarkers for AS diagnosis. [Extracted from the article]

A study conducted by researchers at Oregon Health & Science University (OHSU) investigated the clinical response of patients with ankylosing spondylitis (AS) who received secukinumab, a monoclonal antibody, after an inadequate response to a lower dose. The study found that patients who did not achieve inactive disease after 16 weeks of treatment experienced similar clinical response and safety regardless of dose escalation. The research was supported by Novartis Pharmaceuticals Corporation. The study provides valuable information for patients and healthcare professionals managing AS. [Extracted from the article]

A study conducted by researchers at Zhejiang Chinese Medicine University in Hangzhou, China, aimed to investigate the relationship between ankylosing spondylitis (AS) and different types of cancers. The study analyzed data from 20 cohorts with over 330,000 participants and found that AS was associated with a higher risk of certain cancers, including bone cancer, thyroid gland cancer, multiple myeloma, leukaemia, kidney cancer, prostate cancer, and non-Hodgkin's lymphoma. However, there was no significant correlation between AS and other types of cancers. The researchers concluded that further large-scale studies are needed to consider factors such as AS course, medication histories, and potential biases when examining cancer risk. [Extracted from the article]

Axial Spondyloarthritis (axSpA) is a form of arthritis that primarily affects the spine and sacroiliac joints, causing inflammation and discomfort. It can also impact other joints and organs. There are two types of axSpA: ankylosing spondylitis, which is visible on X-rays, and non-radiographic axSpA, which may not be seen on X-rays but can be detected using MRI. The total prevalent population of axSpA was estimated to be 4.5 million in 2023, with the number of cases expected to increase. While there is no cure for axSpA, treatment aims to alleviate pain and stiffness, maintain joint function, and improve quality of life. Medication, non-drug therapies, lifestyle practices, and surgery may be part of the treatment plan. Several FDA-approved drugs are available for axSpA, including CIMZIA, TALTZ, COSENTYX, RINVOQ, ENBREL, XELJANZ, SIMPONI, and LUMICEF. The market for axSpA is expected to grow significantly, driven by the introduction of new therapies and the rising prevalence of the disease. The pharmaceutical landscape for axSpA has seen advancements with the introduction of biological therapies, and ongoing research aims to expand treatment options. Challenges in early diagnosis and patient adherence to treatment exist, and efforts are being made to develop more precise diagnostic tools and cost [Extracted from the article]

A study conducted at the National University of Medical Sciences (NUMS) in Pakistan examined the safety and clinical response of Etanercept therapy in patients with ankylosing spondylitis. The study found that over 90% of patients had a positive clinical response after three months of treatment with Etanercept. However, patients with comorbid medical conditions or elevated levels of erythrocyte sedimentation rate were more likely to have an inadequate response to the treatment. This research provides valuable insights into the effectiveness of Etanercept therapy for ankylosing spondylitis. [Extracted from the article]

A recent study conducted at Reina Sofia University Hospital in Cordoba, Spain, explored the socioeconomic profiles of patients with ankylosing spondylitis (AS) and their associations with disease severity and disability. The study found that patients with a low socioeconomic profile had longer diagnosis delays, greater body mass index, and more structural damage compared to those with a high socioeconomic profile. Additionally, patients with a low socioeconomic profile had a higher prevalence of permanent disability. The study suggests that socioeconomic status may have implications for the severity and disability of AS, despite similar use of biologic disease-modifying anti-rheumatic drugs. [Extracted from the article]

A study conducted in Harbin, China explored the use of positron emission tomography (PET) in the management of ankylosing spondylitis (AS), a condition characterized by inflammation and osteoblastic changes in the sacroiliac joint. The study found that PET/computed tomography (CT) using aluminium-[18F]fuoride(Al 18 F)-labelled fibroblast activation protein inhibitor (FAPI) was highly sensitive to systemic arthritic changes in AS patients and correlated with clinical disease activity and laboratory tests. The researchers concluded that this imaging method shows promise for early assessment of AS and monitoring disease progression. The study included 20 AS participants and 16 healthy controls. [Extracted from the article]

A study conducted at the Central University Hospital of Asturias (HUCA) examined the use of 18F-FDG positron emission tomography (PET) as a marker for disease activity and treatment response in patients with Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA). The researchers found that 18F-FDG PET showed potential as a marker of disease activity in both AS and PsA, allowing for the monitoring of treatment efficacy. However, there was no significant association between pre-treatment 18F-FDG uptake and subsequent clinical response. This research provides valuable insights into the use of PET imaging in the management of these conditions. [Extracted from the article]

A new report discusses research on the efficacy and safety of a biosimilar of adalimumab (ABP 501; Amgevita) in Iraqi patients with ankylosing spondylitis (AS). The study, conducted at multiple centers in Iraq, involved 72 patients with active AS who were prescribed Amgevita. The data collected from the registry showed that Amgevita was clinically effective and well-tolerated over a 12-month period, with an 82% response rate after 3 months and a 61% response rate after 12 months. The study concluded that ABP501 is a viable treatment option for Iraqi patients with AS. [Extracted from the article]

A recent study conducted at Nagoya University Graduate School of Medicine in Japan examined the clinical features of juvenile onset ankylosing spondylitis (JoAS) in Japanese patients. The study found that the most common initial symptoms of JoAS were pain in the back, hip, and knees. Additionally, more than half of the patients were initially diagnosed with musculoskeletal diseases other than ankylosing spondylitis. This research provides valuable insights into the clinical presentation and diagnosis of JoAS in Japanese patients. [Extracted from the article]

A recent study conducted at the First Medical Center in Beijing, China, explored the use of radiomics-based machine learning to profile hip involvement in ankylosing spondylitis (AS). The researchers extracted radiomic features from pelvis MRI scans of 167 AS patients and used unsupervised machine learning to derive four distinct phenotypes of hip involvement. These phenotypes were found to be predictive of radiographic outcomes, with high-risk phenotypes being three times more likely to have radiological hip lesions. This study confirms the clinical potential of using radiomics to profile hip involvement in AS and improve clinical decision-making. [Extracted from the article]

A patent application titled "Cyclic Peptides For Inhibiting Tnf Receptor 1 Activity" has been published online. The application describes the development of cyclic peptides that selectively inhibit TNFR1, a receptor involved in the signaling of the cytokine tumor necrosis factor alpha (TNFa). These peptides have the potential to treat autoimmune and inflammatory diseases such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriasis, and other conditions that can be treated by blocking TNFa signaling. The invention aims to provide a more targeted and effective treatment option compared to current anti-TNFa biologics. [Extracted from the article]

A recent study conducted by researchers at Huazhong University of Science and Technology explored the therapeutic potential of Mulberroside A (MA) in mitigating intervertebral disc degeneration (IVDD), a common spine disease with inflammation as its main cause. The study found that MA possesses anti-inflammatory characteristics and can up-regulate anabolic-related proteins while decreasing catabolic-related proteins in cells. MA also inhibits the production of pro-inflammatory factors and suppresses the signal transduction of MAPK and NF-kB pathways. In vivo experiments showed that MA mitigated IVDD progression and restored disc height and signal intensity. The study suggests that MA or Ppar-g might be potential drugs or targets for IVDD. [Extracted from the article]

A new report from Hanyang University Hospital for Rheumatic Diseases presents findings on ankylosing spondylitis (AS), a type of arthritis that primarily affects the spine. The study aimed to investigate the factors associated with discontinuation of long-term anti-tumor necrosis factor (TNF) agent use in AS patients. The research found that AS patients on their first anti-TNF treatment for at least two years had a favorable long-term treatment retention rate, with a 24.0% discontinuation rate over a 10.6-year overall survival period. The predictors for discontinuation varied depending on the cause, highlighting the need for personalized approaches to treatment management. [Extracted from the article]

A new study from the University of La Laguna in the Canary Islands has reported findings on ankylosing spondylitis, a musculoskeletal disease. The study examined skeletal remains of a Prehispanic male with fusion in the sacroiliac joints and a bone formation covering the posterior aspect of the right sacroiliac joint. The researchers believe that the individual likely had ankylosing spondylitis, which led to bony fusion and a pelvic fracture. They suggest that the fracture may have been caused by a fall in the mountainous environment where the individual lived. [Extracted from the article]

A case report published by the Connective Tissue Diseases Research Center discusses a 38-year-old female patient with ankylosing spondylitis (AS) who developed skin lesions, including purpuric skin lesions and ischemia of her right foot digits, after starting treatment with adalimumab. The patient was diagnosed with moderate-sized vascular vasculitis associated with adalimumab use. Discontinuation of adalimumab and treatment with high dose glucocorticoids and cyclophosphamide resulted in the resolution of her ischemic lesions. The case highlights the importance of considering drug-related side effects in patients with new skin lesions, particularly in the context of rheumatic diseases such as AS. [Extracted from the article]

A recent report from Dalin Tzu Chi Hospital in Chiayi, Taiwan discusses the role of dysregulated non-coding RNA expression in T cells from patients with ankylosing spondylitis (AS) and its contribution to the immunopathogenesis of the disease. AS is a chronic inflammatory disorder characterized by inflammatory back pain and bony fusion of vertebral joints. The study found that aberrantly expressed non-coding RNAs in AS T cells can lead to abnormal cytokine release, cell signaling abnormalities, and dysregulated cell proliferation and death, all of which contribute to the development of AS. The researchers suggest further investigation in this field to better understand the pathogenesis of AS. [Extracted from the article]

A recent study conducted by Sichuan University in China evaluated the cost-effectiveness of different treatment options for ankylosing spondylitis (AS), a type of arthritis that primarily affects the spine. The study compared conventional care (CC) with seven targeted therapies available in China, including secukinumab, ixekizumab, infliximab, etanercept, adalimumab, golimumab, and tofacitinib. The researchers found that targeted therapies, particularly IL-17 inhibitors, were cost-effective treatments for AS. The choice between brand-new prices or generic drug prices significantly impacted the economic outcomes. [Extracted from the article]

The article focuses on identifying Glutathione Peroxidase 4 (GPx4) as a marker for detecting ferroptosis in patients with ankylosing spondylitis and axial psoriatic arthritis. Topics include the role of GPx4 in ferroptosis detection, its relevance in inflammatory arthritis conditions, and the potential implications for diagnosing and understanding these diseases.

A recent study conducted in Timisoara, Romania, examined the effects of an 8-week exercise program on patients with ankylosing spondylitis (AS). The study found that AS patients had decreased postural stability compared to healthy individuals. However, after participating in the exercise program, the patients showed improvements in postural stability. The study measured static plantar pressure and stabilometry parameters and found significant differences in foot loading sites and center of pressure (CoP) path length before and after rehabilitation. This research provides valuable insights into the potential benefits of exercise for individuals with AS. [Extracted from the article]

The article focuses on a study investigating the relationship between the Ankylosing Spondylitis Disease Activity Score and MRI scoring in patients with ankylosing spondylitis. Topics include the correlation between clinical and MRI assessments, the disease activity of ankylosing spondylitis, and the importance of incorporating MRI for accurate disease evaluation and management.

A new report discusses research findings on ankylosing spondylitis (AS), a chronic inflammatory disease that primarily affects the spine. The study focuses on the prognosis of neurological function in patients with AS cervical fractures and spinal cord injuries (SCIs) who undergo surgical treatment. The researchers analyzed data from 106 patients and found that factors such as spinal hypersignal, preoperative ASIA score, and previous AS drug treatment were associated with postoperative neurological function improvement. However, preoperative T2-weighted spinal hypersignal was identified as an independent risk factor affecting the recovery of neurological function in these patients. [Extracted from the article]

A new report from Beijing, China discusses a case of Bacteroides fragilis induced spondylitis, a rare infection of the spine. The diagnosis was confirmed through blood culture and metagenomic sequencing. The patient had a history of severe oral ulceration, although a direct link to the infection was not established. The report also includes a comprehensive literature review on B. fragilis spondylitis, covering clinical manifestations, diagnostic methods, and treatment strategies. The research was funded by the Gansu Provincial Science and Technology Plan Key Project and the Key project of Health Commission of Gansu Province. [Extracted from the article]

A recent study conducted by researchers at Xi'an Jiaotong University in Shaanxi, China, explored the relationship between necroptosis and ankylosing spondylitis (AS), a type of autoimmune disease. The researchers used bioinformatics to compare gene expressions between AS patients and healthy controls, identifying 18 differentially expressed necroptosis-related genes. Through machine learning algorithms, two hub genes, FASLG and TARDBP, were identified as potential markers for AS diagnosis. The study also suggested that immune cell infiltration, specifically CD4+ T cells, CD8+ T cells, NK cells, and neutrophils, may be associated with the development of AS. These findings provide new insights into the molecular mechanisms of AS and offer potential targets for therapeutic strategies. [Extracted from the article]

A new study conducted by researchers at the Maccabi Institute for Research and Innovation in Tel-Aviv, Israel, evaluated the real-world adherence, drug survival, and discontinuation risk of biologics among patients with ankylosing spondylitis (AS). The study included 343 eligible patients who initiated treatment with biologic disease-modifying anti-rheumatic drugs (bDMARDs) between 2015 and 2018. The results showed that adherence, drug survival, and risk for discontinuation were similar for all tumor necrosis factor alpha inhibitors (TNF-ais) and the interleukin-17 inhibitor (IL-17i) secukinumab, regardless of biologic-experience status. These findings can be useful for healthcare providers in making treatment decisions for patients with AS. [Extracted from the article]